
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is a promising clinical-stage TechBio company, with a unique AI platform that has already shown clinical validation and scalability. The company's diversified pipeline of personalized oncology vaccines and preclinical infectious disease candidates indicates potential for growth and addressing unmet medical needs. Positive partnerships with established pharmaceutical companies could further support Evaxion's development and commercialization plans, but risks such as competition and regulatory challenges should also be considered.
Bears say
Evaxion is expected pivot into autoimmune disease (AID) indications in 2026, with a goal of optimizing their AI-Immunology model to select 2-3 lead indications. The specific indications have not been disclosed, but they will likely be based on targets validated by animal models. This shift in focus could impact Evaxion's licensing strategy and overall financial performance.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares